Sugi Predict

Sugi Predict / Compounds / SCHEMBL1159986

SCHEMBL1159986

SCHEMBL1159986

c1cnc2c(c1)ccc1cc[nH]c12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.58
▸ MAPT P10636 3/20 0.58
▸ CCR1 P32246 3/20 0.58
▸ CCR5 P51681 3/20 0.58
▸ CCR8 P51685 3/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ MMP2 P08253 2/20 0.58
▸ TSHR P16473 2/20 0.58
▸ TP53 P04637 2/20 0.58
▸ GMNN O75496 1/20 0.58
▸ HSP90AA1 P07900 1/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ CYP2D6 P10635 1/20 0.58
▸ MMP9 P14780 1/20 0.58
▸ ALOX15 P16050 1/20 0.58
▸ NFKB1 P19838 1/20 0.58
▸ MMP8 P22894 1/20 0.58
▸ THPO P40225 1/20 0.58
▸ MTOR P42345 1/20 0.58
▸ HTT P42858 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592557 1.00 LMNA (0.58) LMNAMAPTCCR1CCR5CCR8
SCHEMBL18416512 0.87 LMNA (0.52) LMNAMAPTCCR1CCR5CCR8
SCHEMBL31300928 0.79 TET2 (0.55) LMNAMAPTCCR1CCR5CCR8
SCHEMBL8601135 0.79 PSMD14 (0.51) LMNAMAPTCCR1CCR5CCR8
SCHEMBL963923 0.79 TET2 (0.55) LMNAMAPTCCR1CCR5CCR8
SCHEMBL17123043 0.78 MMP2 (0.46) LMNAMAPTCCR1CCR5CCR8
SCHEMBL1501749 0.76 AXL (0.53) LMNAMAPTCCR1CCR5CCR8
SCHEMBL30954657 0.76 ADRA2A (0.42) LMNAMAPTCCR1CCR5CCR8
SCHEMBL6619535 0.76 AXL (0.53) LMNAMAPTCCR1CCR5CCR8
SCHEMBL8600441 0.76 KDM4E (0.47) LMNAMAPTCCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11939319-B2 Pyridinyl and pyrazinyl-(asa)indolsulfonamides UCB PHARMA GMBH (DE) 2024-03-26 — — US claimed
CN-116178692-A Composite material for virus preservation tube and preparation method thereof 深圳市远景医疗器械模具有限公司 2023-05-30 — — CN claimed
EP-3810591-B1 PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES UCB PHARMA GMBH (DE) 2022-08-10 — — EP claimed
US-20210206749-A1 Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides UCB PHARMA GMBH (DE) 2021-07-08 — — US claimed
CN-112469710-A Pyridyl and pyrazinyl- (aza) indole sulfonamides 优时比制药有限公司 2021-03-09 — — CN claimed
EP-4744661-A2 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2026-05-20 — — EP disclosed
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
EP-4298092-B1 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-11-26 — — EP disclosed
US-12410164-B2 Heterocyclic compounds and medical use thereof FONDAZIONE TELETHON (IT) 2025-09-09 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2024-08-27 — — US disclosed
CN-112469710-B Pyridyl and pyrazinyl- (aza) indole sulfonamides 优时比制药有限公司 2024-05-14 — — CN disclosed
WO-2004089913-A1 AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE NOVARTIS AG (CH) 2004-10-21 — — WO disclosed
US-20030162775-A1 Heterocyclic substituted pyrazolones CEPHALON, INC. 2003-08-28 — — US disclosed
CN-1387528-A Heterocyclic substd, pyrazolones CEPHALON INC (US) 2002-12-25 — — CN disclosed
US-6455525-B1 Heterocyclic substituted pyrazolones CEPHALON, INC. 2002-09-24 — — US disclosed
EP-1226141-A1 HETEROCYCLIC SUBSTITUTED PYRAZOLONES CEPHALON, INC. (US) 2002-07-31 — — EP disclosed
US-6365598-B1 FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-02 — — US disclosed
WO-2001032653-A1 HETEROCYCLIC SUBSTITUTED PYRAZOLONES CEPHALON, INC. (US) 2001-05-10 — — WO disclosed
US-3956420-A CPOLYOLEFIN COMPOSITION FOR ELECTRICAL INSULATIONFERROCENE, 8-SUBSTITUTED QUINOLINE DAINICHI-NIPPON CABLES, LTD. (JA) 1976-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162775-A1 Heterocyclic substituted pyrazolones CYP3A4, CYP3A5, PDXK LMNA 2795/4885MAPT 1517/4885CCR1 3090/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB LMNA 1698/4885MAPT 4793/4885CCR1 91/4885
US-20210206749-A1 Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides GPR17, GPR18, GPR119 LMNA 4053/4885MAPT 3406/4885CCR1 2346/4885
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 LMNA 4619/4885MAPT 2850/4885CCR1 2852/4885
US-11939319-B2 Pyridinyl and pyrazinyl-(asa)indolsulfonamides GPR17, GPR18, GPR119 LMNA 4053/4885MAPT 3406/4885CCR1 2346/4885
US-12410164-B2 Heterocyclic compounds and medical use thereof NPPA, NPR1, CYC1 LMNA 3104/4885MAPT 3586/4885CCR1 4051/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB LMNA 1844/4885MAPT 3561/4885CCR1 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.